
Mild Cognitive Impairment Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Mild Cognitive Impairment Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Drugs In Development, 2022, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape.
Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mild Cognitive Impairment - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 15, 8, 11, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1 and 1 molecules, respectively.
Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Drugs In Development, 2022, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape.
Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mild Cognitive Impairment - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 15, 8, 11, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1 and 1 molecules, respectively.
Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Mild Cognitive Impairment (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Mild Cognitive Impairment (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
115 Pages
- Introduction
- Global Markets Direct Report Coverage
- Mild Cognitive Impairment – Overview
- Mild Cognitive Impairment – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Mild Cognitive Impairment – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Mild Cognitive Impairment – Companies Involved in Therapeutics Development
- Actinogen Medical Ltd
- Acumen Pharmaceuticals Inc
- Addex Therapeutics Ltd
- AgeneBio Inc
- Aptinyx Inc
- Araclon Biotech SL
- AstraZeneca Plc
- Biomed Industries Inc
- CereSpir Inc
- CuraSen Therapeutics Inc
- Eisai Co Ltd
- Eli Lilly and Co
- FUJIFILM Toyama Chemical Co Ltd
- Gray Matter
- Grespo AB
- ImmunoChem Therapeutics LLC
- IntelGenx Corp
- INVENT Pharmaceuticals Inc
- Jupiter Neurosciences Inc
- KeifeRx LLC
- Merck & Co Inc
- NeurAegis Inc
- Neuraly Inc
- NKGen Biotech Inc
- NLS Pharmaceutics AG
- Novartis AG
- Novo Nordisk AS
- Octapharma AG
- Partner Therapeutics Inc
- Pfizer Inc
- ProNeurogen Inc
- Sage Therapeutics Inc
- SBI Pharmaceuticals Co Ltd
- SciSparc Ltd
- Shackelford Pharma Inc
- TauRx Therapeutics Ltd
- UCB SA
- Mild Cognitive Impairment – Drug Profiles
- (clenbuterol hydrochloride + nadolol) – Drug Profile
- (CST-2032 + nadolol) – Drug Profile
- ABvac-40 – Drug Profile
- ACU-193 – Drug Profile
- AGB-473 – Drug Profile
- aminolevulinic acid hydrochloride – Drug Profile
- AZD-0328 – Drug Profile
- baricitinib – Drug Profile
- bepranemab – Drug Profile
- bosutinib – Drug Profile
- canakinumab – Drug Profile
- clenbuterol hydrochloride – Drug Profile
- CST-101 – Drug Profile
- DAOI-B – Drug Profile
- donepezil hydrochloride – Drug Profile
- Drug to Inhibit Calpain 2 for Mild Cognitive Impairment – Drug Profile
- Gene Therapy to Activate BDNF for Alzheimer's Disease and Mild Cognitive Impairment – Drug Profile
- GRE-213 – Drug Profile
- hydromethylthionine mesylate – Drug Profile
- immune globulin (human) – Drug Profile
- INV-300 – Drug Profile
- IPW-5371 – Drug Profile
- itanapraced – Drug Profile
- JNS-101 – Drug Profile
- levetiracetam ER – Drug Profile
- levofacetoperane – Drug Profile
- MK-4334 – Drug Profile
- montelukast sodium – Drug Profile
- MW-151 – Drug Profile
- NA-831 – Drug Profile
- nilotinib – Drug Profile
- NLY-001 – Drug Profile
- NN-6535 – Drug Profile
- NYX-458 – Drug Profile
- Peptides for Mild Cognitive Impairment – Drug Profile
- Peptides to Agonize Insulin Receptor for Mild Cognitive Impairment and Alzheimer's Disease – Drug Profile
- PNA-6 – Drug Profile
- SAGE-718 – Drug Profile
- sargramostim – Drug Profile
- Small Molecules to Antagonize MGLUR2 for Cardiovascular and Central Nervous System Disorders – Drug Profile
- SNK-01 – Drug Profile
- SPIP-901 – Drug Profile
- suvorexant – Drug Profile
- T-817MA – Drug Profile
- THX-130 – Drug Profile
- UE-2343 – Drug Profile
- Mild Cognitive Impairment – Dormant Projects
- Mild Cognitive Impairment – Discontinued Products
- Mild Cognitive Impairment – Product Development Milestones
- Featured News & Press Releases
- Mar 31, 2022: Preliminary Study: Drug may be safe in those with mild cognitive impairment, mild dementia
- Mar 15, 2022: Sage Therapeutics announces presentation of encouraging results from the phase 2 PARADIGM Study (Part A) of SAGE-718 in patients with mild cognitive impairment due to Parkinson’s Disease
- Mar 01, 2022: ACW CEO presents at Sachs 15th Annual European Life Sciences Conference
- Nov 09, 2021: CuraSen Therapeutics presents phase 1b clinical data with CST-103 demonstrating significant increases in cerebral blood flow in patients with mild cognitive impairment or Parkinson’s disease
- Apr 06, 2021: Aptinyx recommences phase 2 study of NYX-458 in patients with cognitive impairment associated with Parkinson’s disease dementia and dementia with Lewy bodies
- Jun 04, 2020: Actinogen Medical: Market update and ACW to participate in Bio Digital
- Jan 30, 2020: Aptinyx announces publication of data in movement disorders demonstrating reversal of cognitive deficits with NYX-458 in primate model of Parkinson’s Disease
- Dec 25, 2019: Fujifilm start phase II clinical trial of T-817MA in Europe for treatment of Alzheimer disease
- Dec 05, 2019: Aptinyx initiates phase 2 study of NYX-458 in patients with mild cognitive impairment associated with Parkinson’s disease
- Jul 14, 2019: NeuroActiva announced results of the Phase 2A clinical trial of NA-831 in patients with mild cognitive impairment and mild and moderate Alzheimer’s disease at the AAIC 2019 Conference
- Sep 27, 2017: Therapixs First-in-Class Therapy Demonstrates Reversal of Age-Related Cognitive Impairment in Pre-Clinical Study
- Oct 31, 2016: Therapix Biosciences Successfully Completed the Development of a Formulation for a Tablet for Sublingual Administration of THC for Pharmaceutical Use
- Aug 22, 2016: IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain
- Jul 13, 2016: IntelGenx to Initiate Phase 1 Trial of Montelukast
- Jul 14, 2015: CereSpir Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Mild Cognitive Impairment, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Universities/Institutes, 2022
- Table 5: Products under Development by Companies, 2022
- Table 6: Products under Development by Companies, 2022 (Contd..1)
- Table 7: Products under Development by Universities/Institutes, 2022
- Table 8: Number of Products by Stage and Target, 2022
- Table 9: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 10: Number of Products by Stage and Mechanism of Action, 2022
- Table 11: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 12: Number of Products by Stage and Route of Administration, 2022
- Table 13: Number of Products by Stage and Molecule Type, 2022
- Table 14: Mild Cognitive Impairment – Pipeline by Actinogen Medical Ltd, 2022
- Table 15: Mild Cognitive Impairment – Pipeline by Acumen Pharmaceuticals Inc, 2022
- Table 16: Mild Cognitive Impairment – Pipeline by Addex Therapeutics Ltd, 2022
- Table 17: Mild Cognitive Impairment – Pipeline by AgeneBio Inc, 2022
- Table 18: Mild Cognitive Impairment – Pipeline by Aptinyx Inc, 2022
- Table 19: Mild Cognitive Impairment – Pipeline by Araclon Biotech SL, 2022
- Table 20: Mild Cognitive Impairment – Pipeline by AstraZeneca Plc, 2022
- Table 21: Mild Cognitive Impairment – Pipeline by Biomed Industries Inc, 2022
- Table 22: Mild Cognitive Impairment – Pipeline by CereSpir Inc, 2022
- Table 23: Mild Cognitive Impairment – Pipeline by CuraSen Therapeutics Inc, 2022
- Table 24: Mild Cognitive Impairment – Pipeline by Eisai Co Ltd, 2022
- Table 25: Mild Cognitive Impairment – Pipeline by Eli Lilly and Co, 2022
- Table 26: Mild Cognitive Impairment – Pipeline by FUJIFILM Toyama Chemical Co Ltd, 2022
- Table 27: Mild Cognitive Impairment – Pipeline by Gray Matter, 2022
- Table 28: Mild Cognitive Impairment – Pipeline by Grespo AB, 2022
- Table 29: Mild Cognitive Impairment – Pipeline by ImmunoChem Therapeutics LLC, 2022
- Table 30: Mild Cognitive Impairment – Pipeline by IntelGenx Corp, 2022
- Table 31: Mild Cognitive Impairment – Pipeline by INVENT Pharmaceuticals Inc, 2022
- Table 32: Mild Cognitive Impairment – Pipeline by Jupiter Neurosciences Inc, 2022
- Table 33: Mild Cognitive Impairment – Pipeline by KeifeRx LLC, 2022
- Table 34: Mild Cognitive Impairment – Pipeline by Merck & Co Inc, 2022
- Table 35: Mild Cognitive Impairment – Pipeline by NeurAegis Inc, 2022
- Table 36: Mild Cognitive Impairment – Pipeline by Neuraly Inc, 2022
- Table 37: Mild Cognitive Impairment – Pipeline by NKGen Biotech Inc, 2022
- Table 38: Mild Cognitive Impairment – Pipeline by NLS Pharmaceutics AG, 2022
- Table 39: Mild Cognitive Impairment – Pipeline by Novartis AG, 2022
- Table 40: Mild Cognitive Impairment – Pipeline by Novo Nordisk AS, 2022
- Table 41: Mild Cognitive Impairment – Pipeline by Octapharma AG, 2022
- Table 42: Mild Cognitive Impairment – Pipeline by Partner Therapeutics Inc, 2022
- Table 43: Mild Cognitive Impairment – Pipeline by Pfizer Inc, 2022
- Table 44: Mild Cognitive Impairment – Pipeline by ProNeurogen Inc, 2022
- Table 45: Mild Cognitive Impairment – Pipeline by Sage Therapeutics Inc, 2022
- Table 46: Mild Cognitive Impairment – Pipeline by SBI Pharmaceuticals Co Ltd, 2022
- Table 47: Mild Cognitive Impairment – Pipeline by SciSparc Ltd, 2022
- Table 48: Mild Cognitive Impairment – Pipeline by Shackelford Pharma Inc, 2022
- Table 49: Mild Cognitive Impairment – Pipeline by TauRx Therapeutics Ltd, 2022
- Table 50: Mild Cognitive Impairment – Pipeline by UCB SA, 2022
- Table 51: Mild Cognitive Impairment – Dormant Projects, 2022
- Table 52: Mild Cognitive Impairment – Dormant Projects, 2022 (Contd..1)
- Table 53: Mild Cognitive Impairment – Dormant Projects, 2022 (Contd..2)
- Table 54: Mild Cognitive Impairment – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Mild Cognitive Impairment, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Routes of Administration, 2022
- Figure 10: Number of Products by Molecule Types, 2022
- Figure 11: Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.